63 Great Road Maynard, MA 01754 Phone: 978-897-2800 www.exactlabs.com Don M. Hardison, director, president and CEO NASDAQ:EXAS Overview Exact Sciences Corp. is an applied genomics company that has developed proprietary technologies that may be used for the early detection of several common cancers. It is focusing on colorectal cancer for the first application of its technologies. Its technologies include a three-step sample collection and preparation process and four DNA-based analytical

9640 Towne Centre Drive San Diego, CA 92121 Phone: 858-455-8600 www.discoverypartners.com Riccardo Pigliucci, chairman, president and CEO NASDAQ:DPII Overview Discovery Partners International Inc. is focused on providing the platforms, services and information available to complement the internal drug discovery efforts of pharmaceutical and biopharmaceutical companies. The company offers a range of integrated drug discovery products and services, including computational chemistry

1003 Hamilton Avenue Menlo Park, CA 94025 Phone: 650-752-0200 www.deltagen.com William Matthews, president and CEO NASDAQ:DGEN Overview Deltagen provides data to pharmaceutical and biotechnology companies on the function, role and disease relevance of mammalian genes. Its technology platform is a fully integrated system to validate drug targets and its approach moves from gene identification to the determination of gene function in knockout mouse models to identify the in vivo mammalian

Lynghals 1 IS-110 Reykjavik Iceland Phone: 354-570-1900 www.decode.com Kari Stefansson, president and CEO NASDAQ:DCGN Overview DeCode genetics Inc. is a population-based genomics company conducting research into the inherited causes of common diseases, and operating an ultra-high-throughput genotyping laboratory. The company was founded in August 1996 in Reykjavik, Iceland, making it Iceland’s first biotechnology company. Together with pharmaceutical companies and other health care

6611 Dumbarton Circle Fremont, CA 94555 Phone: 510-505-2100 www.ciphergen.com William E. Rich, president and CEO NASDAQ:CIPH Overview Founded in 1993, Ciphergen Biosystems Inc. is a protein discovery company focused on alleviating the bottleneck in understanding how proteins act in the biology of disease. The company’s ProteinChip System includes ProteinChip Arrays, ProteinChip Reader and ProteinChip Software. The system enables proteomics research and is based on enhanced laser

Gateway Centre 601 Biotech Drive Richmond, VA 23235 Phone: 804-648-3820 www.cbi-biotech.com Robert B. Harris, president NASDAQ:CBTE Overview Commonwealth Biotechnologies Inc. is a contract research organization that performs high-throughput DNA sequence analysis, peptide and DNA synthesis, protein sequencing and amino acid analysis. It said it offers "cutting-edge expertise and a complete array of the most current analytical and synthetic chemistries and biophysical technologies, many of

9881 S. Wilcrest Houston, Texas 77099 Phone: 281-988-6118 www.cytogenix.com Malcolm Skolnick, CEO OTC BB:CYGX Overview CytoGenix Inc. is a biotechnology company conducting research and development of genomic products. The principal area of interest is identifying and commercializing therapeutic applications for the company’s technology for the intracellular expression of single-stranded DNA molecules. Progress to date has demonstrated effective expression for the Oligonucleotide Mediated

Manning Park 15 Fortune Drive Billerica, MA 01821 Phone: 978-663-3660 www.daltonics.bruker.com Frank H. Laukien, chairman, president and CEO NASDAQ:BDAL Overview Bruker Daltonics Inc. manufactures mass spectrometry instruments and accessories for biotechnology and pharmaceutical companies, as well as life sciences, academic institutions and government agencies, with applications in genomics, proteomics, drug discovery, metabolics, microbiology and bioinformatics. Bruker also supplies mass

72 Pinchas Rosen Street Tel Aviv 69512 Israel Phone: 972-3-765-8585 www.compugen.co.il Mor Amitai, CEO NASDAQ:CGEN Overview Compugen combines the fields of advanced mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics. The company’s principal technologies include Gencarta, LEADS, DNA Chip design, Z3 (a high-throughput 2-D gel electrophoresis analysis system) and LabOnWeb.com. LEADS allows thorough mining of expressed sequence tag

210 Kings Way South Melbourne Victoria 3205 Australia Phone: +61 3 9234 1188 www.autogenlimited.com.au Greg Collier, chief scientific officer ASX:AGT Overview Autogen Ltd. is an Australian biotechnology research and development company specializing in using gene discovery approaches to identify novel therapeutic targets, and which has technology platforms in genomics. Autogen’s research and development program has access to a number of human DNA collections derived from various

395 Page Mill Road P.O. Box 10395 Palo Alto, CA 94303 Phone: 650-752-5000 www.agilent.com Edward W. Barnholt, president and CEO NYSE:A Overview Agilent says it is on “the leading edge of nearly every major trend in communications and life sciences.” Its tools and technologies are designed to provide biopharmaceutical companies and research organizations the ability to learn how to turn genetic code into disease cures. Spun off from Hewlett-Packard Co. in 1999, Agilent Technologies

3520 Dunhill Street San Diego, CA 92121 Tel: 858-597-4990 www.amevolution.com William D. Huse, founder and CEO NASDAQ:AMEV Overview Applied Molecular Evolution Inc. applies its directed molecular evolution technology platform, AMEsystem, to improve health care by optimizing and developing human biotherapeutics. AME optimizes the full range of proteins, including antibodies, cytokines, hormones and enzymes, to develop improved versions of currently marketed, FDA-approved biotherapeutics

26 Landsdowne Street Cambridge, MA 02139 Phone: 617-494-0400 www.ariad.com Harvey J. Berger, chairman and CEO NASDAQ:ARIA Overview Ariad Pharmaceuticals Inc. focuses on genomics, proteomics, protein engineering and structure-based drug discovery and development of small-molecule drugs that regulate cell signaling. Ariad has two major research programs. The first centers on discovering and developing inhibitors of signal transduction pathways in cells responsible for osteoporosis and

3200 Walnut Street Boulder, CO 80301 Phone: 303-381-6600 www.arraybiopharma.com Robert Conway, director and CEO NASDAQ:ARRY Overview Founded in 1998, Array BioPharma Inc. is a discovery research company creating drug candidates through innovations in chemistry. Array provides a range of drug discovery products and services, including optimer building blocks, lead generation, lead optimization and process research and development. The company also provides a proprietary chemoinformatics

1288 Pear Avenue Mountain View, CA 94043 Phone: 650-210-1200 www.aclara.com Joseph Limber, president and CEO NASDAQ:ACLA Overview Founded in 1995, Aclara works in the fields of microfluidics, microfabrication, genomics and proteomics. It is applying advances in microfluidics and miniaturization to genetic analysis, drug screening and optimization, and clinical diagnostics. The company specializes in lab-on-a-chip technologies. Aclara’s microfluidic devices use a novel 96-channel design

320 Wakara Way Salt Lake City, UT 84108 Phone: 801-584-3600 www.myriad.com Peter Meldrum, president and CEO NASDAQ:MYGN Overview Founded in 1991, Myriad Genetics is focused on the development of therapeutic and diagnostic products using genomic and proteomic technologies. Its business has five primary objectives: discovering and sequencing genes related to major diseases, identifying upstream and downstream genes to establish biochemical pathways, determining the function and activity of

45 West Gude Drive Rockville, MD 20850 Phone: 240-453-3000 www.celera.com Tony White, president NYSE:CRA Overview The Celera Genomics Group was established in May 1998 by the PE Corp., now Applera Corp., and J. Craig Venter, founder of The Institute for Genomic Research. Celera Genomics and the Applied Biosystems Group comprise Applera Corp. Celera Genomics is engaged mainly in integrating technologies to create therapeutic discovery and development capabilities for internal use and for

9410 Key West Avenue Rockville, MD 20850 Phone: 301-309-8504 www.hgsi.com William Haseltine, chairman and CEO NASDAQ:HGSI Overview Human Genome Sciences Inc., founded in 1992, is a leader in moving genomics-based drugs into clinical trials; it has six drugs in the clinic, including the first of its genomics drugs. Its goal is to discover, develop, manufacture and sell its own genomics-based drugs. HGS has methods of making small quantities of undiscovered proteins, it has isolated a

3160 Porter Drive Palo Alto, CA 94304 Phone: 650-855-0555 www.incyte.com Paul Friedman, CEO NASDAQ:INCY Overview Incyte was founded in 1991 and went public two years later. The company provides genomics technologies and products to the biotechnology and pharmaceutical industries to help prevent, diagnosis and treat disease. Described by Incyte as “the world’s most extensive source of human gene information,” its LifeSeq Gold database provides genomic data and associated full-length clone